These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10458616)

  • 1. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
    Margolis D; Heredia A; Gaywee J; Oldach D; Drusano G; Redfield R
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):362-70. PubMed ID: 10458616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
    Hossain MM; Coull JJ; Drusano GL; Margolis DM
    Antiviral Res; 2002 Jul; 55(1):41-52. PubMed ID: 12076750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.
    Heredia A; Margolis D; Oldach D; Hazen R; Le N; Redfield R
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):406-7. PubMed ID: 10634204
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus.
    Ichimura H; Levy JA
    Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
    Bisset LR; Lutz H; Böni J; Hofmann-Lehmann R; Lüthy R; Schüpbach J
    Antiviral Res; 2002 Jan; 53(1):35-45. PubMed ID: 11684314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase.
    Gavriliu D; Fossey C; Ciurea A; Delbederi Z; Sugeac E; Ladurée D; Schmidt S; Laumond G; Aubertin AM
    Nucleosides Nucleotides Nucleic Acids; 2002; 21(8-9):505-33. PubMed ID: 12484448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures.
    Segal DM; Perez M; Shapshak P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):215-9. PubMed ID: 10077168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
    Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
    Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
    Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S;
    Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
    Limoges J; Persidsky Y; Poluektova L; Rasmussen J; Ratanasuwan W; Zelivyanskaya M; McClernon DR; Lanier ER; Gendelman HE
    Neurology; 2000 Jan; 54(2):379-89. PubMed ID: 10668699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells.
    Yam P; Jensen M; Akkina R; Anderson J; Villacres MC; Wu J; Zaia JA; Yee JK
    Mol Ther; 2006 Aug; 14(2):236-44. PubMed ID: 16647299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
    Davis C; Heredia A; Le N; Dominique JK; Redfield RR
    J Hum Virol; 2001; 4(3):113-22. PubMed ID: 11572234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS; Myrick F; Vela JE; Olson LY; Eisenberg EJ; Borroto-Esodo K; Miller MD; Fridland A
    Antivir Ther; 2005; 10(3):451-7. PubMed ID: 15918336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY; Johns DG; Tanaka M; Mitsuya H
    Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
    Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.